12 / 14
Notes:
Volume 4
Journal of Infectious Diseases and Treatment
ISSN: 2472-1093
Page 32
Euro Infectious Diseases 2018 &
Histopathology 2018
September 27-29, 2018
&
JOINT EVENT
September 27-29, 2018 Rome, Italy
5
th
International Conference on
Histopathology & Cytopathology
10
th
Euro-Global Conference on
Infectious Diseases
Assessing the quality of antimalarial drugs from india using minilab: A field study
Taruna Arora
and
Neena Valecha
National Institute of Malaria Research, India
S
ubstandard and counterfeit antimalarial medicines poses a serious threat to public health. These medicines increases the
mortality by decreasing efficacy; it also increases the threat of emergence of drug resistance, adverse effect from incorrect
excipients/ active ingredients which may be potentially dangerous to the patients. Owing to this, a pilot study was conducted
to survey quality of drugs collected from different malaria endemic areas of India. The survey was conducted in different
geographical regions on the basis of malaria endemicity i.e. Uttar Pradesh (U.P.), Mizoram, Meghalaya, Gujarat, Madhya
Pradesh. A mystery shopper approach was used for collection of samples. The quality of antimalarial drugs from these areas
were assessed by using Global Pharma Health Fund Minilab test kit. This includes physical/visual inspection and disintegration
test, thin-layer chromatography. High performance liquid chromatography was carried out for quantitative assessment of
active pharmaceutical ingredient. A total of 150 antimalarial samples were collected. These samples includes 55 (Chloroqunie),
50 (Artemether Lumefantrine), 14 (Artesunate Sulphadoxine-Pyrimethamine), 31 (Primaquine). These samples were assessed
by quality using GPHF minilab lab kit. In this study 98% of the tablets passed minilab disintegration, 2% consisting did not
passed disintegration test. 99% of samples passed preliminary Qualitative TLC test when compared with 100% and 80% of the
standards. 96% of samples passed quantitative HPLC test, 4% of samples (contained low active pharmaceutical ingredient) did
not passed this test. The substandard drugs circulating in the market causes drug resistance, treatment failure and finally leads
to death. Additional analysis such as post-marketing surveillance should be done so that good quality antimalarials reached
to the population.
Biography
Taruna Arora has completed PhD at the age of 30 years from Uttrakhand Technical University, Dehradun and Post-doctoral studies from National Institute of Malaria
Research, New Delhi, India. She has published more than 14 papers in reputed Journals. She is the member of many societies like Pharmacy Council of India
(PCI), Indian Pharmacological Society (IPS), Society of Biomedical Laboratory Scientists, India (SOBLI).
tarunakatyal@gmail.comTaruna Arora et al., J Infec Dis Treat 2018, Volume 4
DOI: 10.21767/2472-1093-C1-002